Trastuzumab Emtansine (Kadcyla, T-DM1) is another HER2-targeted ADC in a Phase III trial involving patients with HER2-positive early breast cancer and residual invasive disease following neoadjuvant systemic therapy. This evidence concerns the gene ERBB2 and breast cancer.